Skip to main content
Premium Trial:

Request an Annual Quote

CORRECTED: Tranzyme to Produce Cell Lines for Gentris with PGx Applications

This article has been corrected. In a previous version, the name "Gentris," was misspelled and the headline was unclear.

 

NEW YORK, June 24 (GenomeWeb News) - North Carolina biotechnology companies Tranzyme Pharma and Gentris said today that they are collaborating to develop cell lines intended to serve as genetic controls for diagnostic assays used to gauge patients' responses to drug treatments.

 

Morrisville-based Gentris will provide Tranzyme, located in ResearchTrianglePark, with genetic sequences relating to rare, clinically relevant alleles that are implicated in the metabolism of therapeutic compounds, according to an official company statement. Tranzyme will then use its functional biology and gene delivery technology, called TExT, to create recombinant human cell lines expressing the genetic sequences. Financial terms of the deal were not disclosed.

 

In addition, the companies said that they will jointly own the cell lines, and may eventually enter into an additional agreement to commercialize them as genetic controls for FDA-approved diagnostic assays.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.